ReviveMed
ReviveMed is an AI-driven precision medicine company that leverages metabolites and artificial intelligence to revolutionize healthcare. Their patented platform addresses challenges in large-scale metabolomics, enabling the creation of first-in-class generative models and 'metabolic twins'. These virtual patient models simulate health, disease, and treatment response, offering insights into disease mechanisms and predicting patient outcomes. The company focuses on precision obesity and immuno-oncology, developing metabolic twins for conditions like renal cell carcinoma and obesity. ReviveMed's technology assists in optimizing clinical trial design by simulating placebo arms and predicting responders, thereby reducing trial sizes and improving success rates. They also support therapeutic development by identifying novel targets. ReviveMed has established partnerships with biopharma companies and has a pipeline focused on oncology and cardio-metabolic diseases.
ReviveMed
ReviveMed is an AI-driven precision medicine company that leverages metabolites and artificial intelligence to revolutionize healthcare. Their patented platform addresses challenges in large-scale metabolomics, enabling the creation of first-in-class generative models and 'metabolic twins'. These virtual patient models simulate health, disease, and treatment response, offering insights into disease mechanisms and predicting patient outcomes. The company focuses on precision obesity and immuno-oncology, developing metabolic twins for conditions like renal cell carcinoma and obesity. ReviveMed's technology assists in optimizing clinical trial design by simulating placebo arms and predicting responders, thereby reducing trial sizes and improving success rates. They also support therapeutic development by identifying novel targets. ReviveMed has established partnerships with biopharma companies and has a pipeline focused on oncology and cardio-metabolic diseases.
TL;DR
What they do: AI-driven metabolomics platform that builds generative models and metabolic digital twins for precision medicine
Focus areas: Precision obesity, immuno-oncology, oncology, cardio-metabolic diseases
Founded / HQ: 2016; Cambridge, Massachusetts
Founders / leadership: Leila Pirhaji (Co‑Founder & CEO), Ernest Fraenkel (Co‑Founder / Board Member)
Multiple seed / early rounds; reported seed raises including ~$1.5M (2018) and a seed entry dated Jul 13, 2022; total funding reported ~$1.7M